Pharmaceutical Business Review
Anonymous User | Login

Novartis Enters Into Agreement With Tianyuan

Published: 04-Nov-2009

To facilitate the introduction of its vaccines in China, where Novartis currently has a limited presence

As part of a strategic initiative to expand the group's limited presence in China, Novartis has entered into an agreement to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical (Tianyuan). The proposed acquisition will require government and regulatory approvals in China.

As per the collaboration, the two companies are expected to work together to expand Tianyuan's product portfolio and R&D pipeline through targeted investments in vaccines innovation, manufacturing technologies and commercial networks.

The collaboration is also expected to facilitate the introduction of Novartis vaccines into China, where Novartis currently has a limited presence with an offering of vaccines against influenza and rabies.

Daniel Vasella, chairman and CEO of Novartis, said: “Novartis has a long-standing commitment to improving healthcare in China. Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products.”

Ding Xiaohang, founder, chairman and CEO of Tianyuan, said: “Our mission is To build the Great Wall of Health for the people. I personally look forward to working with Novartis to continue our mission by bringing more innovative vaccines to China and building Tianyuan into a true international vaccines company.”

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Solutions4Science

Temperature Mapping and Validation Services ...

Exploristics

Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...

NeuroProof

Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...

DASGIP

Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...

BioKinetic Europe

Phase I/II Contract Research Organisation ...

Toxikon Europe

CRO Providing Preclinical Safety Studies for the Life Science Community ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Merck KGaA

Merck KGaA (Merck) is a Germany-based company engaged in the manufacturing and distribu ...

Wyeth

Wyeth is engaged in developing and providing pharmaceuticals and healthcare products fo ...

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manuf ...

Johnson & Johnson

Johnson & Johnson (J&J) is engaged in the manufacture and sales of broad range of healt ...

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address